Item 7.01 Regulation FD Disclosure

On May 24, 2022, Alaunos Therapeutics, Inc.'s Chief Executive Officer, Kevin S. Boyle Sr., and Vice President of Research & Development, Drew Deniger, Ph.D., gave a presentation at the H.C. Wainwright Global Investment Conference. A copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Item 7.01, including Exhibit 99.1, is being "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"). The information contained in this Item 7.01, including Exhibit 99.1, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act or into any filing or other document pursuant to the Exchange Act, except as otherwise expressly stated in any such filing.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits.

Exhibit No.                                  Description

99.1                Presentation, dated May 2022

104               Cover Page Interactive Data File (embedded within the Inline XBRL
                  document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses